All Series

Thank you for your patience while we update the meetings directory.

Use the tool below to view all available Series

Don’t Miss the Opportunity to Address Persistent CV Risk: Optimizing Outcomes for Ambulatory Patients With HFrEF and LVEF <45%
Don’t Miss the Opportunity to Address Persistent CV Risk: Optimizing Outcomes for Ambulatory Patients With HFrEF and LVEF <45%
Cardiology
Don’t Miss the Opportunity to Address Persistent CV Risk: Optimizing Outcomes for Ambulatory Patients With HFrEF and LVEF <45%
Robert J. Mentz, MD, FHFSA, FACC
- Robert J. Mentz, MD, FHFSA, FACC
EASD 2026: Changing the Set Point—A New Era in Obesity Management on the Horizon
EASD 2026: Changing the Set Point—A New Era in Obesity Management on the Horizon
Obesity
EASD 2026: Changing the Set Point—A New Era in Obesity Management on the Horizon
Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD
- Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD
Amylin Therapies: What's on the Horizon for Obesity and Metabolic Care?
Amylin Therapies: What's on the Horizon for Obesity and Metabolic Care?
Obesity
Amylin Therapies: What's on the Horizon for Obesity and Metabolic Care?
W. Timothy Garvey, MD, MACE, FTOS
- W. Timothy Garvey, MD, MACE, FTOS
EASD 2026: The Evolving PCP Role in Managing Patients With CKM Diseases
EASD 2026: The Evolving PCP Role in Managing Patients With CKM Diseases
Kidney Disease
EASD 2026: The Evolving PCP Role in Managing Patients With CKM Diseases
Ana Maria Cebrián-Cuenca, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
EASD 2026: The Importance of Protecting Lean Muscle Mass in Managing Patients With Obesity
EASD 2026: The Importance of Protecting Lean Muscle Mass in Managing Patients With Obesity
Obesity
EASD 2026: The Importance of Protecting Lean Muscle Mass in Managing Patients With Obesity
Stefan D. Anker, MD, PhD
- Stefan D. Anker, MD, PhD
Connecting the Dots in Obesity Care: Key Takeaways From EASD 2026
Connecting the Dots in Obesity Care: Key Takeaways From EASD 2026
Obesity
Connecting the Dots in Obesity Care: Key Takeaways From EASD 2026
Elisabeth Van Rossum, MD, PhD; William Mencia, MD, FACEHP
- Elisabeth Van Rossum, MD, PhD
- William Mencia, MD, FACEHP
Looking Beyond the Scale: Identifying the Drivers of Obesity
Looking Beyond the Scale: Identifying the Drivers of Obesity
Endocrinology
Looking Beyond the Scale: Identifying the Drivers of Obesity
Elisabeth Van Rossum, MD, PhD; William Mencia, MD, FACEHP
- Elisabeth Van Rossum, MD, PhD
- William Mencia, MD, FACEHP
Changing the Trajectory: Why Earlier Obesity Treatment Matters
Changing the Trajectory: Why Earlier Obesity Treatment Matters
Obesity
Changing the Trajectory: Why Earlier Obesity Treatment Matters
Elisabeth Van Rossum, MD, PhD; William Mencia, MD, FACEHP
- Elisabeth Van Rossum, MD, PhD
- William Mencia, MD, FACEHP
TRIUMPH-2: Translating New Obesity Data Into Real-World Care
TRIUMPH-2: Translating New Obesity Data Into Real-World Care
Obesity
TRIUMPH-2: Translating New Obesity Data Into Real-World Care
Elisabeth Van Rossum, MD, PhD; William Mencia, MD, FACEHP
- Elisabeth Van Rossum, MD, PhD
- William Mencia, MD, FACEHP
CME/CE In-Person & Virtual Event
Beyond the Scale: Assessing the Quality of Weight Loss and Advancing a Whole-Person Approach to Obesity Care
15 november, 2026
Oxon Hill, Maryland
1.25 credits
Unblocking Clinical Inertia: The CMI Era in oHCM Care
Unblocking Clinical Inertia: The CMI Era in oHCM Care
CME/CE Broadcast Replay
Unblocking Clinical Inertia: The CMI Era in oHCM Care
Iacopo Olivotto, MD; Elena Arbelo
0.75 credits
- Iacopo Olivotto, MD
- Elena Arbelo
- Silvia Aguiar
0.75 credits
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Dr. Robert Giugliano
- Dr. Robert Giugliano
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Cardiology
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Javier Morales, MD, FACP, FACE
- Javier Morales, MD, FACP, FACE
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
- Nicholas Marston, MD

All Series

Popular

Title